PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24878316-5 2014 Furthermore, PACAP administration into the VMN resulted in increased tyrosine phosphorylation of the GluN2B subunit of the NMDA receptor, and inhibition of Src kinase activity also blocked the effects of PACAP administration into the VMN on feeding behavior. Tyrosine 69-77 adenylate cyclase activating polypeptide 1 Homo sapiens 13-18 30273693-4 2019 Addition of PACAP-38 to NCI-H838 or A549 cells increased the tyrosine phosphorylation of the EGFR, HER2 and ERK significantly by 4-, 3-, and 2-fold, respectively. Tyrosine 61-69 adenylate cyclase activating polypeptide 1 Homo sapiens 12-17 24878316-6 2014 These results indicate that PACAP neurotransmission in the VMN likely augments glutamate signaling by potentiating NMDA receptors activity through the tyrosine phosphorylation events mediated by the Src kinase family, and modulation of NMDA receptor activity by PACAP in the hypothalamus may be a primary mechanism for its regulation of food intake. Tyrosine 151-159 adenylate cyclase activating polypeptide 1 Homo sapiens 28-33 21898124-0 2012 Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin. Tyrosine 68-76 adenylate cyclase activating polypeptide 1 Homo sapiens 0-50 22581436-0 2012 PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells. Tyrosine 9-17 adenylate cyclase activating polypeptide 1 Homo sapiens 53-103 22581436-3 2012 Also, PACAP receptors (PAC1) regulated the tyrosine phosphorylation of ERK, focal adhesion kinase, and paxillin. Tyrosine 43-51 adenylate cyclase activating polypeptide 1 Homo sapiens 6-11 22581436-4 2012 In this communication, the effects of PACAP on cytosolic Ca(2+) and PYK-2 tyrosine phosphorylation were investigated. Tyrosine 74-82 adenylate cyclase activating polypeptide 1 Homo sapiens 38-43 22581436-7 2012 PACAP-38, but not vasoactive intestinal peptide (VIP), addition to NCI-H838 or H1299 cells significantly increased the tyrosine phosphorylation of PYK-2 after 2 min. Tyrosine 119-127 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 22581436-8 2012 The increase in PYK-2 tyrosine phosphorylation caused by PACAP was inhibited by PACAP(6-38), U73122, or BAPTA, but not H89. Tyrosine 22-30 adenylate cyclase activating polypeptide 1 Homo sapiens 57-62 22581436-8 2012 The increase in PYK-2 tyrosine phosphorylation caused by PACAP was inhibited by PACAP(6-38), U73122, or BAPTA, but not H89. Tyrosine 22-30 adenylate cyclase activating polypeptide 1 Homo sapiens 80-85 22389426-0 2012 Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. Tyrosine 58-66 adenylate cyclase activating polypeptide 1 Homo sapiens 0-50 22389426-5 2012 Western blot analysis indicated that the addition of PACAP but not the structurally related vasoactive intestinal peptide increased EGFR tyrosine phosphorylation in NCI-H838 or H345 cells. Tyrosine 137-145 adenylate cyclase activating polypeptide 1 Homo sapiens 53-58 21898124-1 2012 The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin were investigated using lung cancer cells. Tyrosine 77-85 adenylate cyclase activating polypeptide 1 Homo sapiens 15-65 21898124-1 2012 The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin were investigated using lung cancer cells. Tyrosine 77-85 adenylate cyclase activating polypeptide 1 Homo sapiens 67-72 21898124-2 2012 Addition of PACAP-27 or PACAP-38 but not vasoactive intestinal peptide to NCI-H838 or NCI-H1299 human lung cancer cells significantly increased the tyrosine phosphorylation of FAK or paxillin. Tyrosine 148-156 adenylate cyclase activating polypeptide 1 Homo sapiens 12-17 21898124-2 2012 Addition of PACAP-27 or PACAP-38 but not vasoactive intestinal peptide to NCI-H838 or NCI-H1299 human lung cancer cells significantly increased the tyrosine phosphorylation of FAK or paxillin. Tyrosine 148-156 adenylate cyclase activating polypeptide 1 Homo sapiens 24-29 20219970-5 2010 PACAP receptor (PACR1) stimulation triggered both G(i)alpha and G(s)alpha/cAMP/Epac regulatory cascades resulting in Src kinase activity, which in turn induced TrkA kinase tyrosine phosphorylation. Tyrosine 172-180 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 20219970-7 2010 A single tyrosine (Y(499)) phosphorylation event was identified as critical to both PACAP-mediated transactivation and TrkA-dependent Rit activation. Tyrosine 9-17 adenylate cyclase activating polypeptide 1 Homo sapiens 84-89 16914291-5 2007 In these cells, PACAP increases TrkA tyrosine phosphorylations through a PI-3kinase dependent but phospholipase C independent pathway. Tyrosine 37-45 adenylate cyclase activating polypeptide 1 Homo sapiens 16-21 12409225-4 2002 PACAP-27 or PACAP-38 (100 nM) but not PACAP28-38 or VIP caused increased MAPK tyrosine phosphorylation using NCI-H1299 cells. Tyrosine 78-86 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 12475394-5 2003 Based on results obtained for a truncated VPAC(2) receptor and the closely related PACAP-preferring receptor (PAC(1)) and secretin receptors, we hypothesized that Thr(11) interacted with the VPAC(2) receptor Tyr(184) (similar to the VPAC(1) receptor Phe(200) residue). Tyrosine 208-211 adenylate cyclase activating polypeptide 1 Homo sapiens 83-88 12409225-5 2002 Also, the increase in MAPK tyrosine phosphorylation caused by PACAP-27 was totally inhibited by 10 microM PACAP(6-38), a PAC(1) receptor antagonist or 10 microM PD98059, a MAPKK inhibitor. Tyrosine 27-35 adenylate cyclase activating polypeptide 1 Homo sapiens 62-67 12409225-5 2002 Also, the increase in MAPK tyrosine phosphorylation caused by PACAP-27 was totally inhibited by 10 microM PACAP(6-38), a PAC(1) receptor antagonist or 10 microM PD98059, a MAPKK inhibitor. Tyrosine 27-35 adenylate cyclase activating polypeptide 1 Homo sapiens 106-111 12409225-0 2002 PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Tyrosine 9-17 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 12409225-1 2002 The effects of pituitary adenylate cyclase activating polypeptide (PACAP) on human lung cancer cell line NCI-1299 mitogen activated protein kinase (MAPK) tyrosine phosphorylation and vascular endothelial cell growth factor (VEGF) expression were investigated. Tyrosine 154-162 adenylate cyclase activating polypeptide 1 Homo sapiens 67-72 12409225-2 2002 PACAP-27 (100 nM) increased MAPK tyrosine phosphorylation 3-fold, 5 min after addition to NCI-H1299 cells. Tyrosine 33-41 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 12409225-3 2002 PACAP caused tyrosine phosphorylation in a concentration-dependent manner being half-maximal at 10 nM PACAP-27. Tyrosine 13-21 adenylate cyclase activating polypeptide 1 Homo sapiens 0-5 12409225-3 2002 PACAP caused tyrosine phosphorylation in a concentration-dependent manner being half-maximal at 10 nM PACAP-27. Tyrosine 13-21 adenylate cyclase activating polypeptide 1 Homo sapiens 102-107 32964398-5 2021 The increase in HER2 tyrosine phosphorylation caused by PACAP was inhibited by trastuzumab, a monoclonal antibody (mAb) for HER2, or PACAP(6-38). Tyrosine 21-29 adenylate cyclase activating polypeptide 1 Homo sapiens 133-138 32964398-6 2021 The increase in HER3 tyrosine phosphorylation caused by PACAP was inhibited by HER3 mAb3481 or PACAP(6-38). Tyrosine 21-29 adenylate cyclase activating polypeptide 1 Homo sapiens 56-61 32964398-6 2021 The increase in HER3 tyrosine phosphorylation caused by PACAP was inhibited by HER3 mAb3481 or PACAP(6-38). Tyrosine 21-29 adenylate cyclase activating polypeptide 1 Homo sapiens 95-100 33385499-0 2021 Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases. Tyrosine 95-103 adenylate cyclase activating polypeptide 1 Homo sapiens 38-88 32964398-4 2021 The increase in EGFR tyrosine phosphorylation caused by PACAP was blocked by the EGFR tyrosine kinase inhibitor (TKI) gefitinib, or PACAP(6-38), a PAC1 antagonist. Tyrosine 21-29 adenylate cyclase activating polypeptide 1 Homo sapiens 56-61 32964398-5 2021 The increase in HER2 tyrosine phosphorylation caused by PACAP was inhibited by trastuzumab, a monoclonal antibody (mAb) for HER2, or PACAP(6-38). Tyrosine 21-29 adenylate cyclase activating polypeptide 1 Homo sapiens 56-61